Incyte and Syndax: Niktimvo led to significant disease response rates in patients with recurrent chronic graft-versus-host-disease (cGVHD).
All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic ...